Migraine Market Competitive Dashboard
The prominent players operating the global market are Eisai Inc., Kowa Pharmaceuticals America, Merck, AstraZeneca plc, Eli Lilly and Company, Johnson & Johnson, Meda, Pfizer Inc., Impax Laboratories, OptiNose, Allergan, Luitpold Pharmaceuticals, Abbott Laboratories Inc., Klaria, and GlaxoSmithKline Plc.
Migraine Market Drivers and Constraints Impacting the Market
The global migraine market is estimated to expand rapidly owing to the rising female population across the globe. With increasing healthcare expenditure, growing cigarette consumption, accelerating economic growth, and increasing prevalence of migraine and unmet needs, the global market for migraine is expected to flourish. Moreover, increasing awareness of migraine and its treatments coupled with development of migraine drugs are likely to stimulate the market growth. Also patient expirations are estimated to contribute to the market growth.
On the flip side, high cost, regulatory challenges, and lack of proper diagnosis are considered to dampen the market growth. Moreover, adverse effects of drugs and rising preferences of alternative therapies are presumed to hinder the market growth during the appraisal period.
Global Migraine Market: Segmental Analysis
The migraine market has been segmented on the basis of treatment types, types, drug class, and region.
By mode of type, the global migraine market has been segmented into chronic and episodic.
By mode of treatment type, the global migraine market has been segmented into abortive and preventive. Among these, the abortive treatment comprises therapeutic classes like ergot alkaloids, triptans, NSAIDs, and other non-specific drugs prescribed over-the-counter such as acetaminophen, aspirin, and ibuprofen. The preventive incorporates prescription of off-label and generic medications including beta blockers such as anti-epileptics and atenolol and propranolol like divalproex sodium and topiramate. In the current scenario, Amgen/Novartis’s Aimovig, Allergan’s Botox, and Teva’s Ajovy are the only drugs approved for migraine prevention.
By mode of drug class, the global migraine market has been segmented into ergots, triptans, and others.
Migraine Market Regional Insights
Geographically, migraine market span across Europe, North America, Asia Pacific, and the Middle East and Africa.
Among all the regions, the Asia Pacific region is considered to exhibit a significant growth rate owing to the rising focus of vendors on the emerging markets. The growth in this market is further attributed to the increasing demand for better healthcare facilities and improvements in the healthcare infrastructure. Moreover, this region represents remarkable opportunities for the investors and venture capitalists, as the developed markets are comparatively saturated. Such factors are likely to trigger the demand for migraine market during the appraisal period.
Migraine Industry Updates
November 15, 2018: Indianapolis-based Eli Lilly and Co. has recently applied for approval to the U.S. FDA regarding their new drug in order to treat migraine headaches. Lasmiditan will be used for the acute treatment of certain types of migraines in adults.
Browse Complete Report with TOC @ https://www.marketresearchfuture.com/reports/migraine-market-2381
RELATED REPORTS
Lung Cancer Market Research Report - Global Forecast till 2023
Liquid Biopsy Market Research Report - Global Forecast to 2022
Sleeping Bruxism Treatment Market Research Report - Global Forecast till 2023
About Market Research Future:
Market Research Future (MRFR) is a world-renowned market research company that offers a wide range of services, complete with accurate and precise analysis about diverse markets, sub-markets and target consumers. Our approach is a combination of extensive information and multiple data sources that help provide an exhaustive comprehension about the latest major developments to the client, in addition to future events and what measures and decisions to take on the basis of the same.
